Inhibikase Therapeutics Inc. (IKT) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Inhibikase Therapeutics Inc. (IKT:NASDAQ), powered by AI.

Current Price
$1.67
Sector
Healthcare
What is the Inhibikase Therapeutics Inc. stock price forecast?

Inhibikase Therapeutics Inc. is currently trading at $1.67. View real-time AI analysis on Alpha Lenz.

What is Inhibikase Therapeutics Inc. insider trading activity?

View the latest insider trading data for Inhibikase Therapeutics Inc. on Alpha Lenz.

What is Inhibikase Therapeutics Inc.'s P/E ratio?

View Inhibikase Therapeutics Inc.'s valuation metrics on Alpha Lenz.

Inhibikase Therapeutics Inc.

NASDAQ · IKT
$1.67+0.00(+0.00%)Pre-marketNASDAQ regular session 09:30–16:00 ET
Ask about Inhibikase Therapeutics Inc.'s future dividend policy...
Alpha Chat Insight

Inhibikase Therapeutics Inc.'s ROE is -36.0%. Explore profitability and growth together.

Ask for details

Company Overview

Inhibikase Therapeutics Inc. is a biotechnology company dedicated to the development and commercialization of therapeutics for neurodegenerative diseases and infectious diseases that impact the nervous system. The company focuses on creating innovative drugs aimed at interrupting biological pathways contributing to these diseases. Its leading programs target conditions such as Parkinson’s disease and related disorders, offering potential new treatment options for these debilitating conditions. Inhibikase Therapeutics employs a proprietary platform for drug development, emphasizing the need for precise and effective treatments. The company holds a significant position in the biopharmaceutical sector as it works towards improving healthcare options for neurological conditions. With its ongoing research and development efforts, Inhibikase Therapeutics plays a crucial role in addressing unmet medical needs, contributing to advancements in biotech and medical science.

CEOMr. Mark T. Iwicki
SectorHealthcare
IndustryBiotechnology
Employees15

Company Statistics

FY 2025

Profile

N/AMarket Cap
$0.00Revenue
0.00Shares Out
15Employees

Margins

N/AGross
N/AEBITDA
N/AOperating
N/APre-Tax
N/ANet

Valuation

N/AP/E
N/AP/B
N/AEV/Sales
N/AEV/EBITDA
N/AP/FCF

Growth (CAGR)

N/ARev 3Yr
N/ARev 5Yr
N/AOp Inc 3Yr
N/AOp Inc 5Yr
N/ANet Inc 3Yr
N/ANet Inc 5Yr

Returns

-34.49%ROA
-36.05%ROE
-38.13%ROIC

Financial Health

$139.22MCash & Cash Equivalents
$-130.92MNet Debt
4.80%Debt/Equity
N/AInterest Cov

Frequently Asked Questions

Inhibikase Therapeutics Inc. (ticker: IKT) is a company listed on NASDAQ in the Healthcare sector (Biotechnology). It has approximately 15 employees.

The current price is $1.67 with a P/E ratio of -x and P/B of -x.

ROE is -36.05%.

Alpha Lenz
Singapore
Treasurer Pte Ltd | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2026 Treasurer Pte Ltd. All rights reserved.
Inhibikase Therapeutics Inc. (IKT) Stock Forecast 2026 $1.67 — Price, Financials & Analyst Targets | Alpha Lenz